Statements (86)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:biotechnology
|
| gptkbp:acquisition |
gptkb:Medi_Gene_AG
gptkb:Calithera_Biosciences Acquired the rights to Iclusig from ARIAD Pharmaceuticals. Incyte acquired the rights to Jakafi from Novartis. Acquired the rights to Pemigatinib from the development program. |
| gptkbp:awards |
Received the 2021 Great Place to Work certification.
Received the 2019 Best Places to Work award. Received the 2020 Top Workplaces award. |
| gptkbp:ceo |
gptkb:Hervé_Hoppenot
|
| gptkbp:clinical_trial |
cardiology
endocrinology metabolic disorders neurology oncology pediatrics autoimmune diseases inflammation rheumatology psychiatry dermatology Phase 3 trials infectious diseases pain management ophthalmology geriatrics gynecology urology gastroenterology nephrology pulmonology addiction medicine hematology-oncology Conducts clinical trials for new drugs. Focuses on autoimmune diseases. Focuses on hematology and oncology. Focuses on rare diseases. Focuses on solid tumors. |
| gptkbp:collaboration |
gptkb:Genentech
gptkb:Astra_Zeneca gptkb:Pfizer gptkb:Merck_&_Co. |
| gptkbp:focus |
gptkb:cancer_treatment
inflammation treatment |
| gptkbp:founded |
gptkb:1991
|
| gptkbp:founder |
gptkb:Paul_Friedman
|
| gptkbp:headcount |
1,500+
|
| gptkbp:headquarters |
gptkb:Wilmington,_Delaware
gptkb:Wilmington,_Delaware,_USA |
| https://www.w3.org/2000/01/rdf-schema#label |
Incyte Corporation
|
| gptkbp:industry |
gptkb:pharmaceuticals
Pharmaceuticals |
| gptkbp:key_people |
gptkb:Herbert_H._Schwartz
gptkb:David_W._G._H._Hyman Herbert L. W. Hoernig |
| gptkbp:number_of_employees |
1,000+ (2021)
|
| gptkbp:partnership |
gptkb:Bristol-Myers_Squibb
gptkb:Novartis Collaboration with Eli Lilly Collaboration with Merck & Co. Collaboration with Novartis |
| gptkbp:philanthropy |
Supports educational initiatives.
Supports cancer research initiatives. Supports community health programs. Supports diversity and inclusion programs. Supports patient assistance programs. |
| gptkbp:products |
gptkb:Iclusig
gptkb:Jakafi gptkb:Pemigatinib |
| gptkbp:research_focus |
molecular biology
biomarkers drug discovery hematology genomics therapeutics solid tumors |
| gptkbp:revenue |
$1.1 billion (2020)
|
| gptkbp:stock_symbol |
gptkb:INCY
|
| gptkbp:subsidiary |
gptkb:Incyte_Biosciences
gptkb:Incyte_Biosciences,_Inc. gptkb:Incyte_Europe_Ltd. gptkb:Incyte_Pharmaceuticals,_Inc. |
| gptkbp:traded_on |
gptkb:NASDAQ
|
| gptkbp:website |
www.incyte.com
|
| gptkbp:bfsParent |
gptkb:Biogen
|
| gptkbp:bfsLayer |
4
|